Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1758

1.

The Brain-Gut-Microbiome Axis.

Martin CR, Osadchiy V, Kalani A, Mayer EA.

Cell Mol Gastroenterol Hepatol. 2018 Apr 12;6(2):133-148. doi: 10.1016/j.jcmgh.2018.04.003. eCollection 2018. Review.

PMID:
30023410
2.

Update on FXR Biology: Promising Therapeutic Target?

Han CY.

Int J Mol Sci. 2018 Jul 16;19(7). pii: E2069. doi: 10.3390/ijms19072069. Review.

3.

Ablation of carotenoid cleavage enzymes (BCO1 and BCO2) induced hepatic steatosis by altering the farnesoid X receptor/miR-34a/sirtuin 1 pathway.

Lim JY, Liu C, Hu KQ, Smith DE, Wang XD.

Arch Biochem Biophys. 2018 Jul 11;654:1-9. doi: 10.1016/j.abb.2018.07.007. [Epub ahead of print]

PMID:
30006135
4.

FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.

Lv B, Ma L, Tang W, Huang P, Yang B, Wang L, Chen S, Gao Q, Zhang S, Xia J.

Cell Physiol Biochem. 2018 Jul 12;48(1):158-172. doi: 10.1159/000491715. [Epub ahead of print]

5.

Investigation of the hepatoprotective effect of Corydalis saxicola Bunting on carbon tetrachloride-induced liver fibrosis in rats by 1H-NMR-based metabonomics and network pharmacology approaches.

Liu XW, Tang CL, Zheng H, Wu JX, Wu F, Mo YY, Liu X, Zhu HJ, Yin CL, Cheng B, Ruan JX, Song FM, Chen ZN, Song H, Guo HW, Liang YH, Su ZH.

J Pharm Biomed Anal. 2018 Jul 2;159:252-261. doi: 10.1016/j.jpba.2018.06.065. [Epub ahead of print]

PMID:
29990893
6.

Lipid reducing activity of novel cholic acid (CA) analogs: Design, synthesis and preliminary mechanism study.

Luo G, Qian Z, Qiu R, You Q, Xiang H.

Bioorg Chem. 2018 Jul 5;80:396-407. doi: 10.1016/j.bioorg.2018.07.002. [Epub ahead of print]

PMID:
29986186
7.

Simultaneous inhibition of FXR and TGR5 exacerbates atherosclerotic formation.

Miyazaki-Anzai S, Masuda M, Kohno S, Levi M, Shiozaki Y, Keenan AL, Miyazaki M.

J Lipid Res. 2018 Jul 5. pii: jlr.M087239. doi: 10.1194/jlr.M087239. [Epub ahead of print]

8.

Synthesis and biological evaluation of novel SIPI-7623 derivatives as farnesoid X receptor (FXR) antagonists.

Nian SY, Wang GP, Jiang ZL, Xiao Y, Huang MH, Zhou YH, Tan XD.

Mol Divers. 2018 Jul 4. doi: 10.1007/s11030-018-9843-2. [Epub ahead of print]

PMID:
29974364
9.

Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis.

Byun S, Kim DH, Ryerson D, Kim YC, Sun H, Kong B, Yau P, Guo G, Xu HE, Kemper B, Kemper JK.

Nat Commun. 2018 Jul 3;9(1):2590. doi: 10.1038/s41467-018-04697-5.

10.

Glycyrrhizin alleviates non-alcoholic steatohepatitis via modulating bile acids and meta-inflammation.

Yan T, Wang H, Cao L, Wang Q, Takahashi S, Yagai T, Li G, Krausz KW, Wang G, Gonzalez FJ, Hao H.

Drug Metab Dispos. 2018 Jun 29. pii: dmd.118.082008. doi: 10.1124/dmd.118.082008. [Epub ahead of print]

PMID:
29959134
11.

Farnesoid X Receptor Activation Enhances Transforming Growth Factor β-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma Cells.

Kainuma M, Takada I, Makishima M, Sano K.

Int J Mol Sci. 2018 Jun 28;19(7). pii: E1898. doi: 10.3390/ijms19071898.

12.

INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function.

Comeglio P, Cellai I, Mello T, Filippi S, Maneschi E, Corcetto F, Corno C, Sarchielli E, Morelli A, Rapizzi E, Bani D, Guasti D, Vannelli GB, Galli A, Adorini L, Maggi M, Vignozzi L.

J Endocrinol. 2018 Aug;238(2):107-127. doi: 10.1530/JOE-17-0557.

13.

Farnesoid X Receptor (FXR) Interacts with Camp Response Element Binding Protein (CREB) to Modulate Glucagon-Like Peptide-1 (7-36) Amide (GLP-1) Secretion by Intestinal L Cell.

Li P, Zhu L, Yang X, Li W, Sun X, Yi B, Zhu S.

Cell Physiol Biochem. 2018 Jun 21;47(4):1442-1452. doi: 10.1159/000490836. [Epub ahead of print]

14.

Enterococcus faecium WEFA23 from infant lessens high-fat-diet-induced hyperlipidemia via cholesterol 7-alpha-hydroxylase gene by altering the composition of gut microbiota in rats.

Huang F, Zhang F, Xu D, Zhang Z, Xu F, Tao X, Qiu L, Wei H.

J Dairy Sci. 2018 Jun 20. pii: S0022-0302(18)30583-6. doi: 10.3168/jds.2017-13713. [Epub ahead of print]

PMID:
29935822
15.

Structural insights into the heterodimeric complex of the nuclear receptors FXR and RXR.

Zheng W, Lu Y, Tian S, Ma F, Wei Y, Xu S, Li Y.

J Biol Chem. 2018 Jun 22. pii: jbc.RA118.004188. doi: 10.1074/jbc.RA118.004188. [Epub ahead of print]

16.

Progress and challenges of selective Farnesoid X receptor modulation.

Massafra V, Pellicciari R, Gioiello A, van Mil SWC.

Pharmacol Ther. 2018 Jun 20. pii: S0163-7258(18)30111-6. doi: 10.1016/j.pharmthera.2018.06.009. [Epub ahead of print] Review.

17.

Organic Solute Transporter α-β Protects Ileal Enterocytes From Bile Acid-Induced Injury.

Ferrebee CB, Li J, Haywood J, Pachura K, Robinson BS, Hinrichs BH, Jones RM, Rao A, Dawson PA.

Cell Mol Gastroenterol Hepatol. 2018 Jan 12;5(4):499-522. doi: 10.1016/j.jcmgh.2018.01.006. eCollection 2018.

18.

Cholestasis-induced bile acid elevates estrogen level via farnesoid X receptor-mediated suppression of the estrogen sulfotransferase SULT1E1.

Liu X Sr, Xue R, Yang C, Gu J, Chen S, Zhang S.

J Biol Chem. 2018 Jun 21. pii: jbc.RA118.001789. doi: 10.1074/jbc.RA118.001789. [Epub ahead of print]

19.

FXR-Mediated Cortical Cholesterol Accumulation Contributes to the Pathogenesis of Type A Hepatic Encephalopathy.

McMillin M, Grant S, Frampton G, Petrescu AD, Kain J, Williams E, Haines R, Canady L, DeMorrow S.

Cell Mol Gastroenterol Hepatol. 2018 Mar 6;6(1):47-63. doi: 10.1016/j.jcmgh.2018.02.008. eCollection 2018.

20.

Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Bahar R, Wong KA, Liu CH, Bowlus CL.

Gastroenterol Hepatol (N Y). 2018 Mar;14(3):154-163.

Supplemental Content

Loading ...
Support Center